Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment

Dow Jones

06/10

By Doc Louallen

Harrow shares advanced after the ophthalmic company relaunched a treatment for vernal keratoconjunctivitis, an allergic eye disease that primarily affects children.

Shares were recently up 9.5% at $34.64. The stock is up 22% in the past month.

The company said Verkazia, a calcineurin inhibitor immunomodulator, targets the underlying inflammation in VKC, and may reduce reliance on steroid "rescue" therapies. It carries risks such as glaucoma and cataract formation.

"Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, steroid-sparing treatment," Chief Executive Mark Baum said.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

June 10, 2026 11:08 ET (15:08 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2642142243"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642142243\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642142243?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642142243","market":"sg","top_or_hot":-1,"title":"Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Doc Louallen \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Harrow shares advanced after the ophthalmic company relaunched a treatment for vernal keratoconjunctivitis, an allergic eye disease that primarily affects children. \n</p>\n<p>\n  Shares were recently up 9.5% at $34.64. The stock is up 22% in the past month. \n</p>\n<p>\n  The company said Verkazia, a calcineurin inhibitor immunomodulator, targets the underlying inflammation in VKC, and may reduce reliance on steroid \"rescue\" therapies. It carries risks such as glaucoma and cataract formation. \n</p>\n<p>\n  \"Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, steroid-sparing treatment,\" Chief Executive Mark Baum said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 11:08 ET (15:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-10 23:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Doc Louallen \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Harrow shares advanced after the ophthalmic company relaunched a treatment for vernal keratoconjunctivitis, an allergic eye disease that primarily affects children. \n</p>\n<p>\n  Shares were recently up 9.5% at $34.64. The stock is up 22% in the past month. \n</p>\n<p>\n  The company said Verkazia, a calcineurin inhibitor immunomodulator, targets the underlying inflammation in VKC, and may reduce reliance on steroid \"rescue\" therapies. It carries risks such as glaucoma and cataract formation. \n</p>\n<p>\n  \"Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, steroid-sparing treatment,\" Chief Executive Mark Baum said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 11:08 ET (15:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642142243","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642142243","pubTimestamp":1781104080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares were recently up 9.5% at $34.64. The stock is up 22% in the past month.The company said Verkazia, a calcineurin inhibitor immunomodulator, targets the underlying inflammation in VKC, and may reduce reliance on steroid \"rescue\" therapies. It carries risks such as glaucoma and cataract formation.\"Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, steroid-sparing treatment,\" Chief Executive Mark Baum said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4007":"制药","HROW":"Harrow Health Inc"},"translate_title":"哈罗股价因重新推出儿童眼病治疗而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"By Doc Louallen \n\n\n \n\n\n  Harrow shares advanced after the ophthalmic company relaunched a treatment for vernal keratoconjunctivitis, an allergic eye disease that primarily affects children. \n\n\n  Shares were recently up 9.5% at $34.64. The stock is up 22% in the past month. \n\n\n  The company said Verkazia, a calcineurin inhibitor immunomodulator, targets the underlying inflammation in VKC, and may reduce reliance on steroid \"rescue\" therapies. It carries risks such as glaucoma and cataract formation. \n\n\n  \"Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, steroid-sparing treatment,\" Chief Executive Mark Baum said. \n\n\n \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 11:08 ET (15:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}